(MedPage Today) — Levacetylleucine (Aqneursa) improved neurologic symptoms and functioning in adults and children with ataxia-telangiectasia in a phase III, randomized, crossover trial. The primary endpoint was the mean 12-week change in Scale…
Source: MedPage Today — Headlines
